



# Pfizer Global Medical Grants

Discovery, support and collaboration





# About Us

## Who We Are

Pfizer Global Medical Grants (GMG) is an industry-leading, global grants and collaborations program. GMG supports over \$100 million USD of externally-driven research, education and improvement science initiatives annually, via competitive grant programs and an open online portal. Information about the program and a link to the grants portal is available on the website [www.pfizer.com/about/programs-policies/grants](http://www.pfizer.com/about/programs-policies/grants).

## What We Do

GMG is dedicated to ensuring that patients, healthcare providers and researchers around the world have the tools and resources they need to ensure healthcare solutions reach patients in the right way and at the right time.

Our goal is to improve the quality, safety and effectiveness of healthcare by empowering healthcare communities to develop local solutions that impact global health.

# Our Impact

Pfizer GMG supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need.

## Our Commitment to Health Equity

GMG enables Pfizer to support organizations, institutions, and initiatives to reach patients most in need – furthering Pfizer's commitment to health equity.

Today, GMG is working to democratize access to our grant programs so that more investigators and researchers are able to apply. We're doing this by expanding our reach to developing countries and regions, as well as driving outreach to underserved communities.

GMG encourages submissions for unique projects of high scientific caliber to result in the best outcome for patients. At Pfizer GMG, we believe every person deserves equal access to optimal care.

## A Unique Approach

Via the provision of independent grants and other competitive grant programs, GMG is bridging the gap between science and patients. However, GMG is unique to the medical grants industry in that GMG does not solely provide grants. In addition, the team engages external partners to identify solutions that help resolve issues in order to see real impact. GMG partners with organizations to advance their goals in areas that overlap with Pfizer's medical and/or scientific strategies.

## Patients First

GMG's support of external organizations includes patient education and patient support programs. Competitive grant programs often include patient-directed learning and change strategies in order to help improve patient outcomes.





# GMG Support Opportunities



## Research Collaborations (RC)

Pfizer promotes RCs by partnering with investigators and organizations (Collaborators) to generate innovative research of potential scientific value to patients, physicians and the greater scientific community. Collaborators may be academic institutions, research networks, cooperative groups, government agencies or other entities.

Similar to an ISR, a Collaborator is responsible for carrying out the research in accordance with the study protocol and, unless country-specific laws require otherwise, acting as the regulatory sponsor of the study. Pfizer's contribution may include funding, investigational product(s), device(s), equipment or other forms of research support. Unlike an ISR in the RC context, Pfizer can contribute to research design and statistical plan. Pfizer reviews and approves the study protocol and any informed consent documents, has study oversight capabilities and may access patient-level data to facilitate its own research, development, commercialization and other activities. To explore a research collaboration opportunity, please send questions and inquiries to [researchcollaborations@pfizer.com](mailto:researchcollaborations@pfizer.com)



## Investigator Sponsored Research (ISR)

ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides financial and/or non-financial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This grant is used as support for pre-clinical and clinical studies (including interventional and non-interventional), that involve a Pfizer medicine (e.g., commercial drug, investigational drug, pure compound\*).

Qualified researchers are invited to submit Investigator Sponsored Research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at [www.pfizer.com/isr](http://www.pfizer.com/isr). All proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement.



## General Research Grants

General research projects can be focused on the development or refinement of specific and defined medical knowledge. This grant type is used to support research that does not include the study of a Pfizer asset, including health services research, registry development and queries, and outcomes research.



## Quality Improvement (QI)

QI is a type of grant which consists of Pfizer funding to support independent projects for systematic and continuous actions that lead to measurable improvement in health care services and the health status of individuals and targeted patient groups. QI considers aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice. QI grants help improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies. For more information on Quality Improvement initiatives, please visit: [www.pfizer.com/quality-improvement](http://www.pfizer.com/quality-improvement)



## Medical Education

Medical Education is a type of grant which consists of Pfizer funding for independent medical education activities or initiatives which serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional (e.g. continuing medical education, continuing health education, continuing education). These activities or initiatives may or may not be accredited.

Eligible organizations can request funding to host a medical expert to foster educational exchanges with local healthcare providers who can benefit from the expert's knowledge and on-site presence. For more details regarding eligibility, areas of interest, and educational goals for the current year, please visit: [www.pfizer.com/independentmeded](http://www.pfizer.com/independentmeded)





# Annual Meetings

Pfizer GMG recognizes knowledge exchange as an important component of the continuing education continuum and offers support for these programs through independent medical grants.

Eligible organizations can request funding to support in-person or virtual national and regional conferences and congresses. For more details regarding eligibility, areas of interest, and educational goals for the current year, please visit: [www.pfizer.com/independentmeded](http://www.pfizer.com/independentmeded)

Our commitment is to review all proposals and send out decision notifications by the notification deadlines below:

<b>Application Cycle*</b>	<b>To Submit Live Activity Must Start On or After</b>	<b>Decision Communicated By</b>
Jan 1 – Feb 15	Apr 1	Mar 16
Mar 1 – Apr 15	Jul 1	Jun 1
Jun 1 – Jul 15	Oct 1	Aug 31
Sept 1 – Oct 15	Jan 1	Nov 30

\*Applications may be submitted earlier, but not later, than the relevant application cycle.

Important note for applicants: Please do not wait until the submission deadline to enter your request into the online portal. Plan to apply early to allow time for clarification questions and to ensure completeness.

# Appendix

# Appendix: Oncology Global Medical Grants

## Pfizer's Commitment to the Oncology Community

Pfizer helps to improve outcomes for patients through the provision of independent grants in support of research, education, and healthcare quality improvement.

In 2021, through the Oncology Global Medical Grants program, Pfizer approved 495 projects for investigator-sponsored research, independent medical education and quality improvement. The grants were awarded in 53

countries, with the potential to initially impact more than 8million patients. The potential patient impact over time is even greater given that it is estimated that globally 1 in 5 people develop cancer in their lifetime. Together with researchers, clinicians, professional organizations, and patients, we are committed to help improve the lives of people with cancer, as well as their families and caregivers.

## 2021 Investigator Sponsored Research Grants

### Quarterly Application and Review Cycles

Submission Window	Notification deadline: *
January 7 - March 31	May 26
April 1 - May 31	July 28
June 1 - August 31	October 27
September 1 - January 5, 2023	March 2

Important note for applicants: Please do not wait until the submission deadline to enter your request into the online portal. Plan to apply early to allow time for clarification questions and to ensure completeness.

Oncology Assets Available for Investigator Sponsored Research.



Compound Name	Compound Target
Avelumab**	PD-L1
Axitinib	VEGFR 1, 2, and 3
Bevacizumab-bvzr*	VEGF-A
Binimetinib*****	MEK
Bosutinib	BCR-Abl, Src
Crizotinib	c-MET, ALK, ROS1
Dacomitinib	EGFR
Elranatamab	BCMA-CD3
Encorafenib*****	RAF
Enzalutamide***	Androgen Receptor
Gemtuzumab ozogamicin	CD33
Inotuzumab ozogamicin	CD22
Lorlatinib	ALK, ROS1
Palbociclib	CDK4/6
Relugolix****	GnRH
Rituximab-pvvr*	CD20
Sasanlimab	PD-L1
Sunitinib	VEGFR1-3, PDGFR, KIT, FLT-3, RET
Talazoparib	PARP
Trastuzumab—qyyp*	HER2

- \* Biosimilar
- \*\* Co-developed with Merck KGaA, Darmstadt, Germany
- \*\*\* Co-developed with Astellas
- \*\*\*\* Co-developed with Myovant
- \*\*\*\*\* Co-developed with Pierre Fabre and Ono Pharmaceutical